Cellectis SA (NASDAQ:CLLS)’s share price gapped up prior to trading on Monday . The stock had previously closed at $27.39, but opened at $27.59. Cellectis SA shares last traded at $28.18, with a volume of 55,804 shares changing hands.

A number of brokerages have issued reports on CLLS. Jefferies Group restated a “buy” rating on shares of Cellectis SA in a report on Friday, August 5th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $65.00 target price on shares of Cellectis SA in a report on Wednesday, July 27th. Zacks Investment Research cut Cellectis SA from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. Finally, Piper Jaffray Cos. restated a “buy” rating on shares of Cellectis SA in a report on Sunday, May 8th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Cellectis SA currently has a consensus rating of “Buy” and a consensus target price of $43.60.

The company has a 50 day moving average price of $26.44 and a 200-day moving average price of $26.95. The firm’s market cap is $994.49 million.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.